NasdaqGS:RIGL Earnings and Revenue History March 15th 2025 Zooming In On Rigel Pharmaceuticals' Earnings. One key financial ratio used to measure how well a company converts its p ...

Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

Lamar County Sheriff Danny Rigel has documented 40 years of his law enforcement career in a binder. Most officers would use crime reports or newspaper clippings Rigel prefers hand-drawn cartoons.

SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that ...

Citi analyst Yigal Nochomovitz raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $55 from $49 and keeps a Buy rating on the ...

B. Riley raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $24 from $20 and keeps a Neutral rating on the shares following the ...

Analysts at HC Wainwright issued their Q3 2025 EPS estimates for Rigel Pharmaceuticals in a research report issued to clients ...

These increases were partially offset by decreased research and development costs due to the timing of clinical trial activities related to R289, Rigel's dual IRAK 1/4 inhibitor program ...

Tabit has secured $46.3mn time charter with HMM Company Ltd; Rigel will be delivered to Global Horizon Shipping for $42.8mn ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4, 2025. Rigel senior ...

Rigel reported a strong third quarter in 2024, with revenue of $55.3 million, significantly beating the consensus estimate of $38.3 million. This performance was largely driven by the impressive ...